Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, United States.
Front Immunol. 2020 Jun 9;11:1160. doi: 10.3389/fimmu.2020.01160. eCollection 2020.
Pulmonary infection is a leading cause of hospitalization in world. Lung damage due to infection and host mediated pathology can have life threatening consequences. Factors that limit lung injury and/or promote epithelial barrier function and repair are highly desirable as immunomodulatory therapeutics. Over the last decade, interleukin-22 has been shown to have pulmonary epithelial protective functions at the mucosal immune interface with bacterial and viral pathogens. This article summarizes recent findings in this area and provides perspective regarding the role of IL-22 in mucosal host defense.
肺部感染是导致全球住院的主要原因。感染和宿主介导的病理导致的肺部损伤可能会产生危及生命的后果。因此，作为免疫调节治疗方法，能够限制肺部损伤和/或促进上皮屏障功能和修复的因素是非常需要的。在过去十年中，白细胞介素-22 已被证明在与细菌和病毒病原体的黏膜免疫界面具有肺上皮保护功能。本文总结了这一领域的最新发现，并就白细胞介素-22 在黏膜宿主防御中的作用提供了一些观点。
